PMID- 25599619
OWN - NLM
STAT- MEDLINE
DCOM- 20150521
LR  - 20181202
IS  - 1759-507X (Electronic)
IS  - 1759-5061 (Linking)
VI  - 11
IP  - 3
DP  - 2015 Mar
TI  - Clinical trials. Rituximab for maintenance of remission in AAV.
PG  - 131-2
LID - 10.1038/nrneph.2014.254 [doi]
AB  - Maintenance therapy for antineutrophil cytoplasmic antibody-associated vasculitis 
      (AAV) should reduce rates of relapse with minimal toxicity. The MAINRITSAN 
      trial-the first randomized controlled trial to compare the efficacies of 
      rituximab and azathioprine in AAV remission maintenance- has demonstrated a 
      superior outcome using rituximab. These data have important implications for the 
      management of AAV.
FAU - Tanna, Anisha
AU  - Tanna A
AD  - Renal and Vascular Inflammation Section, Department of Medicine, Imperial College 
      London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK.
FAU - Pusey, Charles
AU  - Pusey C
AD  - Renal and Vascular Inflammation Section, Department of Medicine, Imperial College 
      London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK.
LA  - eng
PT  - Comment
PT  - Journal Article
DEP - 20150120
PL  - England
TA  - Nat Rev Nephrol
JT  - Nature reviews. Nephrology
JID - 101500081
RN  - 0 (Antibodies, Monoclonal, Murine-Derived)
RN  - 0 (Immunosuppressive Agents)
RN  - MRK240IY2L (Azathioprine)
SB  - IM
CON - N Engl J Med. 2014 Nov 6;371(19):1771-80. PMID: 25372085
MH  - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/*drug therapy
MH  - Antibodies, Monoclonal, Murine-Derived/*therapeutic use
MH  - Azathioprine/*therapeutic use
MH  - Female
MH  - Humans
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Male
EDAT- 2015/01/21 06:00
MHDA- 2015/05/23 06:00
CRDT- 2015/01/21 06:00
PHST- 2015/01/21 06:00 [entrez]
PHST- 2015/01/21 06:00 [pubmed]
PHST- 2015/05/23 06:00 [medline]
AID - nrneph.2014.254 [pii]
AID - 10.1038/nrneph.2014.254 [doi]
PST - ppublish
SO  - Nat Rev Nephrol. 2015 Mar;11(3):131-2. doi: 10.1038/nrneph.2014.254. Epub 2015 
      Jan 20.